Aktiv-Dry LLC Profile last edited on: 9/2/2023
CAGE: 3MHQ2
UEI: XKXUNMZJMKJ8
Business Identifier: Development of vaccines that can be stored dry and inhaled 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 02
County: Boulder
Congr. District: 02
County: Boulder
Public Profile
AKTIV-DRY LLC, a spin-out company formed from University of Colorado, provides dry powder stabilization and processing solutions for the vaccine, pharmaceutical, and biotechnology industries. The company is particularly interested in particle stabilization, synthesis, drying and coating technologies. AKTIV-DRY has a proven track record in micronizing and gently drying vaccines, antibodies, enzymes, proteins and other pharmaceutical compounds. AKTIV-DRY engineers particle sizes and morphology to satisfy your requirements. Licenses are available for the patents and intellectual property shown on the page with that name. The firm is trying to develop a measles vaccine that can be stored dry and inhaled which turns it into glassy particles surrounding a matrix of trehalose, the sugar that allows brine shrimp cysts to survive dried out for years but hatch into wriggling creatures in seawater.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2013 | 2 | NIH | $1,139,918 | |
| Project Title: Stability And Functionality Of The Immunoject Single-Dose, Auto-Reconstitution De | ||||
| 2013 | 1 | NIH | $149,998 | |
| Project Title: Thermostable Sublingual Measles Vaccine Dry Wafers | ||||
| 2009 | 2 | NIH | $923,612 | |
| Project Title: Development of a Micronized Needle-Free Nicotine Vaccine for Smoking Cessation an | ||||
| 2008 | 1 | NIH | $99,990 | |
| Project Title: Aktiv-Neb: A Dry Powder Inhaler For Anti-Rsv Sirna Microparticles | ||||
| 2006 | 2 | USDA | $375,985 | |
| Project Title: A New Process for Producing Phytosterol and Lycopene Nano- and Micro-Particles | ||||
Key People / Management
Brian Quinn -- President
Stephen P Cape -- Chief Scientific Officer
Pankaj Pathak -- Research Scientist
James Arthur Searles
Robert E Sievers -- Chief Executive Officer
Stephen P Cape -- Chief Scientific Officer
Pankaj Pathak -- Research Scientist
James Arthur Searles
Robert E Sievers -- Chief Executive Officer
